Pradhan T K, Qian J M, Sutliff V E, Mantey S A, Jensen R T
Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-1804, USA.
Am J Physiol. 1995 Apr;268(4 Pt 1):G605-12. doi: 10.1152/ajpgi.1995.268.4.G605.
Functional studies suggest that guinea pig chief cells have both cholecystokinin-A (CCK-A) and CCK-B receptors (CCK-A-R and CCK-B-R, respectively). However, all efforts to directly characterize the specific CCK-A-R using binding have been unsuccessful. Recent studies describe specific CCK-A-R agonists such as A-71378 ([desamino-Nle28,31-(N-methyl)Asp32]CCK heptapeptide]. In the present study, [D-Tyr-Gly]A-71378 was synthesized, which has > 300-fold selectivity for CCK-A-R and can be iodinated. [D-Tyr-Gly]A-71378 was equipotent to A-71378 in stimulating pepsinogen release from purified guinea pig chief cells. Binding of 125I-labeled [D-Tyr-Gly]A-71378 was saturable and specific. Potencies for inhibiting binding were as follows: [D-Tyr-Gly]A-71378 = A-71378 = 4x CCK octapeptide (CCK-8) > 1,000x des(SO4)-CCK-8, gastrin. In contrast, for 125I-gastrin binding they were CCK-8 > gastrin-17-I > des(SO4)-CCK-8 >> A-71378 or [D-Tyr-Gly]A-71378. Binding of [D-Tyr-Gly]A-71378 was best fitted by a two-site model. In contrast, 125I-gastrin binding was fitted with a single-site model. For inhibiting binding of 125I-[D-Tyr-Gly]A-71378, the CCK antagonists had relative affinities of L-364,718 >> L-365,260, and the reverse was true with 125I-gastrin. Correlation of binding with changes in biological activity suggested low-affinity CCK-A-R were mediating these changes. These results demonstrate directly for the first time that guinea pig chief cells possess CCK-A-R and CCK-B-R. The pharmacology of these CCK-A-R resembles those on other tissues. This novel, highly selective CCK-A ligand should be useful because it will identify CCK-A-R when they make up as little as 0.2% of the total CCK receptor number.
功能研究表明,豚鼠主细胞同时具有胆囊收缩素-A(CCK-A)和CCK-B受体(分别为CCK-A-R和CCK-B-R)。然而,所有试图通过结合实验直接鉴定特定CCK-A-R的努力均未成功。最近的研究描述了特定的CCK-A-R激动剂,如A-71378([去氨基-Nle28,31-(N-甲基)Asp32]CCK七肽)。在本研究中,合成了[D-Tyr-Gly]A-71378,它对CCK-A-R具有超过300倍的选择性,并且可以碘化。[D-Tyr-Gly]A-71378在刺激纯化的豚鼠主细胞释放胃蛋白酶原方面与A-71378等效。125I标记的[D-Tyr-Gly]A-71378的结合是可饱和的且具有特异性。抑制结合的效力如下:[D-Tyr-Gly]A-71378 = A-71378 = 4倍胆囊收缩素八肽(CCK-8)> 1000倍去(SO4)-CCK-8、胃泌素。相比之下,对于125I-胃泌素结合,它们的效力顺序为CCK-8 > 胃泌素-17-I > 去(SO4)-CCK-8 >> A-71378或[D-Tyr-Gly]A-71378。[D-Tyr-Gly]A-71378的结合最适合用双位点模型拟合。相比之下,125I-胃泌素结合用单位点模型拟合。对于抑制125I-[D-Tyr-Gly]A-71378的结合,CCK拮抗剂的相对亲和力为L-364,718 >> L-365,260,而对于125I-胃泌素结合则相反。结合与生物活性变化的相关性表明,低亲和力的CCK-A-R介导了这些变化。这些结果首次直接证明豚鼠主细胞具有CCK-A-R和CCK-B-R。这些CCK-A-R的药理学特性与其他组织上的相似。这种新型的、高度选择性的CCK-A配体应该会很有用,因为当CCK-A-R仅占总CCK受体数量的0.2%时它就能识别CCK-A-R。